Adma生物制品 ADMA 深 沪
等待开盘 03-26 09:30:00 美东时间
9.915
-1.415
-12.49%
华盛通- 最 高11.41
- 今 开11.41
- 成交量 2282.23万股
- 最 低 8.62
- 昨 收 11.33
- 总市值 23.60亿
- 52周最高 25.67
- 市盈率 静 16.52
- 换手率 9.59%
- 52周最低 8.62
- 委 比 11.03%
- 总股本 2.38亿
- 历史最高 25.67
- 量 比 2.95
- 振 幅 24.62%
- 历史最低 1.01
- 每 手 1
- 风险率 2.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
ADMA Biologics shares drop after Culper Research short report alleges financial misreporting; company pushes back.
今天 01:22
BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma
BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - U.S. stock index futures climbed on Wednesday
03-25 19:45
BUZZ-ADMA Biologics rises after rejecting short-seller report
BUZZ-ADMA Biologics rises after rejecting short-seller report ** Shares of biotech firm ADMA Biologics ADMA.O rise about 3% to $11.63 premarket ** ADMA rejects a negative report by Culper Research, which has a short position in the stock ** Culper on March 24 accused the company of inflating its sal
03-25 18:43
ADMA Responds To Short-Seller Report, Reviewing Assertions For Accuracy
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a
03-25 18:35
ADMA Biologics Addresses Misleading Short-Seller Report
ADMA Biologics Inc. (Nasdaq: ADMA) addressed a negative research report published by Culper Research, which holds a short position in ADMA. The Company emphasized its commitment to accurate and compliant financial disclosures and criticized the report for being speculative and containing misleading statements. ADMA manufactures and markets FDA-approved biologics for immune deficiency treatments. It is reviewing the report's claims and continues t...
03-25 10:30
ADMA Biologics President and CEO Adam S. Grossman disposes of USD 318,360 in common shares
ADMA Biologics President and CEO Adam S. Grossman disposes of USD 318,360 in common shares Adam Grossman, President and CEO of ADMA Biologics, reported a disposal of 21,000 common shares on March 16, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artific
03-18 09:01
ADMA Biologics announces $125M accelerated share repurchase with JPmorgan
ADMA Biologics (ADMA) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) a...
03-02 20:46
ADMA Biologics launches $125 million accelerated share repurchase with JPMorgan
ADMA Biologics launches $125 million accelerated share repurchase with JPMorgan ADMA Biologics announced a planned 2026 share repurchase initiative of about $200 million, including a $125 million accelerated share repurchase agreement with JPMorgan under its existing program authorizing up to $500 m
03-02 20:00
ADMA Biologics Files Initial Beneficial Ownership Statement for CFO and Treasurer Terry Kohler
ADMA Biologics Files Initial Beneficial Ownership Statement for CFO and Treasurer Terry Kohler ADMA Biologics Inc. filed an initial statement of beneficial ownership for Terry Kohler, CFO and Treasurer. The full filing can be accessed through the link below. Disclaimer: This news brief was created b
02-27 10:00
财报速睇 | Adma生物制品 2025财年年度营收5.10亿美元，同比增长19.6%；归母净利润1.47亿美元，同比下滑25.7%
华盛资讯2月26日讯，Adma生物制品公布2025财年年度业绩，公司年度营收5.10亿美元，同比增长19.6%，归母净利润1.47亿美元，同比下滑25.7%。
02-26 08:47
